

# Congxin Dai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7306869/publications.pdf>

Version: 2024-02-01

17  
papers

270  
citations

1163117  
8  
h-index

996975  
15  
g-index

18  
all docs

18  
docs citations

18  
times ranked

421  
citing authors

#	ARTICLE	IF	CITATIONS
1	Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. <i>Nature Genetics</i> , 2017, 49, 75-86.	21.4	74
2	Mature myelin maintenance requires Qki to coactivate PPAR $\beta$ -RXR $\alpha$ -mediated lipid metabolism. <i>Journal of Clinical Investigation</i> , 2020, 130, 2220-2236.	8.2	50
3	The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas. <i>Frontiers in Endocrinology</i> , 2020, 11, 608422.	3.5	37
4	Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review. <i>Frontiers in Oncology</i> , 2021, 11, 773905.	2.8	15
5	How to Classify and Define Pituitary Tumors: Recent Advances and Current Controversies. <i>Frontiers in Endocrinology</i> , 2021, 12, 604644.	3.5	14
6	Qki regulates myelinogenesis through Srebp2-dependent cholesterol biosynthesis. <i>ELife</i> , 2021, 10, .	6.0	13
7	Qki is an essential regulator of microglial phagocytosis in demyelination. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	13
8	The Application of Artificial Intelligence and Machine Learning in Pituitary Adenomas. <i>Frontiers in Oncology</i> , 2021, 11, 784819.	2.8	12
9	Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor. <i>Molecular Medicine</i> , 2022, 28, 34.	4.4	10
10	Surgical outcome of transsphenoidal surgery in Cushing's disease: a case series of 1106 patients from a single center over 30 years. <i>Endocrine</i> , 2022, 75, 219-227.	2.3	8
11	A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer. <i>Pharmacological Research</i> , 2021, 174, 105931.	7.1	7
12	Outcomes of Transsphenoidal Surgery in Cushing Disease Patients with Negative Pituitary Magnetic Resonance Imaging Findings: A Single-Center Experience. <i>Endocrine Practice</i> , 2020, 26, 1320-1330.	2.1	5
13	Evolution of a refractory prolactin-secreting pituitary adenoma into a pituitary carcinoma: report of a challenging case and literature review. <i>BMC Endocrine Disorders</i> , 2021, 21, 217.	2.2	5
14	MicroRNA-30d target TIMP3 induces pituitary tumor cell growth and invasion. <i>Gland Surgery</i> , 2021, 10, 3314-3323.	1.1	3
15	Is Seed and Soil Theory Suitable for Metastatic Spread of Pituitary Carcinomas?. <i>Frontiers in Endocrinology</i> , 2020, 11, 607405.	3.5	2
16	From "Aggressive" to "Refractory": Advances and Controversies in the Definition and Classification of Pituitary Tumors. <i>Endocrine Practice</i> , 2020, 26, 1384-1386.	2.1	2
17	Transsphenoidal Surgery of Corticotroph Adenomas With Cavernous Sinus Invasion: Results in a Series of 86 Consecutive Patients. <i>Frontiers in Oncology</i> , 2022, 12, 810234.	2.8	0